In a retrospective study, we calculated the treatment costs of 63 patients who received either autologous bone marrow transplantation (ABMT) with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) (filgrastim) (n=13) or without r-metHuG-CSF (n=22) or altenatively, peripheral blood progenitor cell (PBPC) transplantation mobilised by r-metHuG-CSF (n=28). The recovery of granulocytes, platelets and reticulocytes after PBPC was markedly accelerated as compared with ABMT with or without r-metHuG-CSF. The accelerated haematopoietic recovery was associated with a reduction in platelets and red blood cell transfusion requirements, with a reduction in episodes of fever and with earlier discharge from the hospital. This resulted in the average cost per treatment of the PBPC group being almost 30% lower than the treatment costs in the ABMT groups.

, , , , ,,
European Journal of Cancer
Erasmus School of Health Policy & Management (ESHPM)

Uyl-de Groot, C., Richel, D., & Rutten, F. (1994). Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation. European Journal of Cancer, 30(11), 1631–1635. doi:10.1016/0959-8049(94)00328-3